• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical outcomes and costs associated with in-hospital biliary complications after liver transplantation: a cross-sectional analysis.肝移植术后院内胆道并发症的临床结局及成本:一项横断面分析。
J Gastrointest Surg. 2015 Feb;19(2):282-9. doi: 10.1007/s11605-014-2675-1. Epub 2014 Oct 16.
2
Changing pattern of biliary complications in an evolving liver transplant unit.不断发展的肝移植中心胆系并发症模式的变化
Liver Transpl. 2017 Apr;23(4):478-486. doi: 10.1002/lt.24736.
3
Biliary complications adversely affect patient and graft survival after liver retransplantation.胆道并发症会对肝移植后患者和移植物的存活产生不利影响。
Liver Transpl. 2013 Sep;19(9):965-72. doi: 10.1002/lt.23696. Epub 2013 Aug 18.
4
Patient and Graft Survival: Biliary Complications after Liver Transplantation.患者和移植物存活率:肝移植术后胆道并发症。
J Am Coll Surg. 2018 Apr;226(4):484-494. doi: 10.1016/j.jamcollsurg.2017.12.039. Epub 2018 Jan 31.
5
Strategies That Reduce 90-Day Readmissions and Inpatient Costs After Liver Transplantation.肝移植后降低 90 天再入院率和住院费用的策略。
Liver Transpl. 2018 Nov;24(11):1561-1569. doi: 10.1002/lt.25186.
6
Costs Associated With Early Vascular and Biliary Complications in Liver-Transplanted Patients in a Hospital in Antioquia, Colombia 2019: A Case Series.2019 年哥伦比亚安蒂奥基亚一家医院肝移植患者早期血管和胆道并发症相关成本:病例系列。
Value Health Reg Issues. 2020 Dec;23:131-136. doi: 10.1016/j.vhri.2020.06.004. Epub 2020 Nov 19.
7
Recipient-associated risk factors for post-liver transplantation biliary complications: A cohort study.肝移植后胆道并发症的受者相关危险因素:一项队列研究。
Indian J Gastroenterol. 2024 Aug;43(4):791-798. doi: 10.1007/s12664-023-01479-w. Epub 2024 Jan 3.
8
National assessment of early biliary complications after liver transplantation: economic implications.肝移植术后早期胆道并发症的全国性评估:经济影响
Transplantation. 2014 Dec 15;98(11):1226-35. doi: 10.1097/TP.0000000000000197.
9
Endoscopic treatment of pediatric post-transplant biliary complications is safe and effective.内镜治疗小儿移植后胆道并发症是安全有效的。
Dig Endosc. 2015 May;27(4):505-511. doi: 10.1111/den.12420. Epub 2015 Feb 4.
10
Biliary cast syndrome following liver transplantation: Predictive factors and clinical outcomes.肝移植术后胆管铸型综合征:预测因素及临床结局
Liver Transpl. 2008 Oct;14(10):1466-72. doi: 10.1002/lt.21492.

引用本文的文献

1
Factors affecting anxiety, depression, and self-care ability in patients who have undergone liver transplantation.影响肝移植患者焦虑、抑郁和自我护理能力的因素。
World J Gastroenterol. 2021 Oct 28;27(40):6967-6984. doi: 10.3748/wjg.v27.i40.6967.
2
Bile microbiota: new insights into biliary complications in liver transplant recipients.胆汁微生物群:对肝移植受者胆道并发症的新见解。
Ann Transl Med. 2020 Mar;8(6):354. doi: 10.21037/atm.2020.02.60.
3
Biliary complications in liver transplantation: Impact of anastomotic technique and ischemic time on short- and long-term outcome.肝移植中的胆道并发症:吻合技术和缺血时间对短期及长期预后的影响。
World J Transplant. 2015 Dec 24;5(4):300-9. doi: 10.5500/wjt.v5.i4.300.
4
Autologous mobilized peripheral blood CD34(+) cell infusion in non-viral decompensated liver cirrhosis.自体动员外周血CD34(+)细胞输注治疗非病毒性失代偿期肝硬化
World J Gastroenterol. 2015 Jun 21;21(23):7264-71. doi: 10.3748/wjg.v21.i23.7264.

本文引用的文献

1
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.CMX001 预防造血细胞移植中的巨细胞病毒病。
N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.
2
Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm.利用供体/受者临床算法安全使用高度脂肪变性的肝脏。
Clin Transplant. 2013 Sep-Oct;27(5):732-41. doi: 10.1111/ctr.12211. Epub 2013 Sep 2.
3
Liver defatting: an alternative approach to enable steatotic liver transplantation.肝脏去脂:实现脂肪肝肝移植的一种替代方法。
Am J Transplant. 2012 Dec;12(12):3176-83. doi: 10.1111/j.1600-6143.2012.04288.x. Epub 2012 Oct 11.
4
Biliary complications following orthotopic liver transplantation: a 10-year audit.肝移植术后胆道并发症:10 年回顾性分析
HPB (Oxford). 2011 Jun;13(6):391-9. doi: 10.1111/j.1477-2574.2011.00300.x.
5
Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications.肝移植术后胆系并发症的风险因素:肝移植物脂肪变性。
Clin Transplant. 2010 Sep-Oct;24(5):631-5. doi: 10.1111/j.1399-0012.2009.01128.x.
6
Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation.原位肝移植术后缺血型胆损伤的发生率及危险因素。
Transpl Int. 2010 Jan;23(1):14-22. doi: 10.1111/j.1432-2277.2009.00947.x. Epub 2009 Aug 18.
7
Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate storage/reperfusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition.米诺环素和N-甲基-4-异亮氨酸环孢素(NIM811)通过抑制线粒体通透性转换减轻大鼠肝移植后的储存/再灌注损伤。
Hepatology. 2008 Jan;47(1):236-46. doi: 10.1002/hep.21912.
8
Who pays for biliary complications following liver transplant? A business case for quality improvement.肝移植术后胆道并发症的费用由谁承担?质量改进的商业案例。
Am J Transplant. 2006 Dec;6(12):2978-82. doi: 10.1111/j.1600-6143.2006.01575.x.
9
Retrograde reperfusion via vena cava lowers the risk of initial nonfunction but increases the risk of ischemic-type biliary lesions in liver transplantation--a randomized clinical trial.经腔静脉逆行再灌注降低肝移植初始无功能风险,但增加缺血型胆管病变风险——一项随机临床试验
Transpl Int. 2006 Sep;19(9):738-48. doi: 10.1111/j.1432-2277.2006.00347.x.
10
Risk factors for biliary complications after liver transplantation.肝移植术后胆道并发症的危险因素。
Arch Surg. 2004 Oct;139(10):1101-5. doi: 10.1001/archsurg.139.10.1101.

肝移植术后院内胆道并发症的临床结局及成本:一项横断面分析。

Clinical outcomes and costs associated with in-hospital biliary complications after liver transplantation: a cross-sectional analysis.

作者信息

Palanisamy Arun P, Taber D J, Sutter A G, Nadig S N, Dowden J E, McGillicuddy J W, Baliga P K, Chavin K D

机构信息

Division of Transplant Surgery, Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 412, Charleston, SC, 29425, USA,

出版信息

J Gastrointest Surg. 2015 Feb;19(2):282-9. doi: 10.1007/s11605-014-2675-1. Epub 2014 Oct 16.

DOI:10.1007/s11605-014-2675-1
PMID:25319035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4305464/
Abstract

INTRODUCTION

In-hospital biliary complications (BCs) after liver transplantation (LT) are reported in up to 20 % of patients and contribute to poor outcomes and increased costs. Existing single-center outcome and cost analyses studies are limited in scope.

METHODS

This is a cross-sectional analysis of national data involving 7,967 patients transplanted between 2011 and 2012 with the primary aim of determining the association between BCs and clinical outcomes and costs. Age, race, diagnosis, and severity of illness are associated with the development of BCs.

RESULTS

BCs develop in 14.6 % of LT recipients and have substantial implications for perioperative outcomes, including length of hospital and ICU stay (27.9 vs 19.6 mean days, p < 0.001 and 12.0 vs 8.3 mean days, p < 0.001, respectively), in-hospital morbidity (39 vs 27 %, p < 0.001), 30-day readmissions (14.8 vs 11.2 %, p < 0.001), and in-hospital mortality (5.8 vs 4.0 %, p < 0.001). BCs contributed to a mean increase in in-hospital costs of $36,212 (p < 0.001), due to increases in accommodations ($9,539, p < 0.001), surgical services ($3,988, p < 0.001), and pharmacy services ($8,445, p < 0.001).

DISCUSSION

BCs are a predominant etiology for in-hospital morbidity and mortality, while contributing significantly to the high cost of LT. Efforts should be focused on understanding salient and modifiable risk factors, while developing innovative strategies to reduce BCs.

摘要

引言

肝移植(LT)后院内胆道并发症(BCs)在高达20%的患者中被报道,会导致不良预后并增加成本。现有的单中心结局和成本分析研究范围有限。

方法

这是一项对国家数据的横断面分析,涉及2011年至2012年间接受移植的7967例患者,主要目的是确定BCs与临床结局及成本之间的关联。年龄、种族、诊断和疾病严重程度与BCs的发生有关。

结果

14.6%的肝移植受者发生BCs,对围手术期结局有重大影响,包括住院时间和重症监护病房(ICU)停留时间(平均27.9天对19.6天,p<0.001;平均12.0天对8.3天,p<0.001)、院内发病率(39%对27%,p<0.001)、30天再入院率(14.8%对11.2%,p<0.001)和院内死亡率(5.8%对4.0%,p<0.001)。由于住宿费用增加(9539美元,p<0.001)、手术服务费用增加(3988美元,p<0.001)和药房服务费用增加(8445美元,p<0.001),BCs导致院内成本平均增加36212美元(p<0.001)。

讨论

BCs是院内发病和死亡的主要病因,同时对肝移植的高成本有重大影响。应致力于了解显著且可改变的风险因素,同时制定创新策略以减少BCs。